全文获取类型
收费全文 | 260篇 |
免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 3篇 |
基础医学 | 5篇 |
临床医学 | 18篇 |
内科学 | 11篇 |
皮肤病学 | 1篇 |
神经病学 | 128篇 |
特种医学 | 68篇 |
外科学 | 17篇 |
综合类 | 1篇 |
预防医学 | 3篇 |
药学 | 2篇 |
肿瘤学 | 2篇 |
出版年
2024年 | 1篇 |
2020年 | 5篇 |
2019年 | 3篇 |
2018年 | 3篇 |
2017年 | 6篇 |
2016年 | 1篇 |
2015年 | 3篇 |
2014年 | 1篇 |
2013年 | 4篇 |
2012年 | 7篇 |
2011年 | 11篇 |
2010年 | 9篇 |
2009年 | 5篇 |
2008年 | 20篇 |
2007年 | 20篇 |
2006年 | 13篇 |
2005年 | 13篇 |
2004年 | 19篇 |
2003年 | 9篇 |
2002年 | 14篇 |
2001年 | 18篇 |
2000年 | 7篇 |
1999年 | 9篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1996年 | 2篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 3篇 |
1991年 | 3篇 |
1990年 | 5篇 |
1988年 | 1篇 |
1987年 | 4篇 |
1986年 | 3篇 |
1985年 | 4篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 4篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1976年 | 2篇 |
1975年 | 3篇 |
1974年 | 1篇 |
排序方式: 共有261条查询结果,搜索用时 0 毫秒
71.
72.
Huttner HB Jüttler E Hug A Köhrmann M Schellinger PD Steiner T 《Der Nervenarzt》2006,77(6):671-2, 674-6, 678-81
Intracerebral hemorrhage (ICH) is the most serious complication of oral anticoagulant therapy (OAT). The growing use of OAT has resulted in an increase of fatal ICH. The mortality rate is about 65%, and most of the surviving patients remain disabled. While improvements in the treatment of spontaneous ICH have recently been described, there are no internationally accepted guidelines for managing patients with OAT-ICH. Therefore, identifying effective treatments is essential for improving clinical outcome. This article reviews the epidemiology of OAT-ICH, its pathophysiology, and current treatment options and discusses open questions with particular respect to more recent pharmacological therapies. 相似文献
73.
74.
75.
76.
77.
Thomalla G Köhrmann M Röther J Schellinger PD 《Fortschritte der Neurologie-Psychiatrie》2007,75(6):343-350
Intravenous thrombolysis with tPA is the only approved and effective treatment for acute ischemic stroke. The approval, however, is restricted to treatment within 3 hours of stroke onset, and it is not recommended to treat patients beyond 80 years of age. Due to these restrictions, thrombolysis is only given to a small number of acute stroke patients. At the same time there is growing evidence that patients can be treated with thrombolysis safely and effectively even beyond these restrictions. We give an overview over the published data regarding thrombolysis beyond the 3 hour time window and in patients aged 80 or over. Based on these data we conclude that (1.) intravenous thrombolysis in MRI selected patients is safe and effective within an extended time window of up to 6 hours, and (2.) there is no increase in mortality or symptomatic intracerebral bleeding complications in patients aged 80 or over treated with thrombolysis. A great number of acute stroke patients reaches the hospital beyond the 3 hour time window, and there is a growing number of old and very old stroke patients in the western world. Treating patients up to a 6 hour time window and beyond the age of 80 years would clearly increase the number of patients, which might benefit from this effective treatment. To summarize, we recommend experienced stroke centres to treat acute stroke patients with thrombolysis up to 6 hours using MRI criteria for patient selection, and to treat also patients aged 80 years or older. 相似文献
78.
Juttler E Kohrmann M Schellinger PD 《Nature clinical practice. Cardiovascular medicine》2006,3(12):656-663
Ischemic stroke is a leading cause of death and disability in the Western world. At present, intravenous administration of tissue plasminogen activator within 3 h of symptom onset is the only proven effective treatment to re-establish cerebral blood flow in the case of acute vessel occlusion. Unfortunately, few patients presenting with acute ischemic stroke qualify for intravenous tissue plasminogen activator therapy. The focus of current research is, therefore, to find new treatment options by which to obtain early reperfusion, and to extend the therapeutic window for intervention beyond 3 h. The purpose of this Review is to provide an integrated view of the current state of reperfusion therapy in patients with acute stroke, including pharmacologic agents and the methods of delivery. The focus will be on intravenous and intra-arterial use of plasminogen activators in acute supratentorial infarction. Other therapies, such as antiplatelet agents (i.e. glycoprotein IIb/IIIa inhibitors), and anticoagulant drugs will be discussed briefly. 相似文献
79.
80.